HTI 501

Drug Profile

HTI 501

Alternative Names: HTI-501; Recombinant human cathepsin L - Halozyme Therapeutics; rHuCAT-L

Latest Information Update: 29 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Halozyme Therapeutics
  • Class
  • Mechanism of Action Cathepsin L modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cellulite

Most Recent Events

  • 31 May 2015 HTI 501 is still in phase I/II trials for Cellulite in Mexico
  • 25 Mar 2014 Top-line efficacy & adverse events data from a phase I/II trial Cellulite released by Halozyme Therapeutics
  • 07 Aug 2013 Halozyme Therapeutics completes enrolment in its phase I/II trial for Cellulite in Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top